Multicenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 755
- 试验地点
- 92
- 主要终点
- Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
研究概览
简要总结
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral anticoagulant (NOAC) in patients with atrial fibrillation. This study is also done to learn how the drug in this study moves into, through and out of the body. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.
Apixaban, works by reducing the production of blood clotting factors in our body and thins the blood and is a so called non-vitamin K oral anticoagulant (NOAC). Thinning the blood can prevent you from blood clots which can cause a stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must be 45 years of age or older at the time of signing the informed consent.
- •Participant with AF documented by ECG evidence with
- •CHA2DS2-VASc score ≥ 2 if male or CHA2DS2-VASc score ≥ 3 if female
- •Indication for treatment with an oral anticoagulant in
- •any participant currently not treated with an oral anticoagulant (e.g. treatment naïve) or alternatively,
- •participant on a NOAC in case of at least one bleeding risk feature (history of a prior bleed within the last 12 months requiring medical attention and / or moderate renal dysfunction with eGFR 30-50 ml/min and / or current clinically indicated antiplatelet therapy with Acetylsalicylic acid(ASA) ≤ 100 mg)
- •Written informed consent
排除标准
- •Mechanical heart valve prosthesis
- •Any degree of rheumatic mitral stenosis or moderate-to-severe, non-rheumatic mitral stenosis
- •Atrial fibrillation due to a reversible cause, participants in sinus rhythm after successful ablation, or plan for cardioversion or ablation during study conduct
- •Requirement for chronic anticoagulation (for a different indication than AF) or antiplatelet therapy (up to 100 mg ASA is allowed). Anticipated need for chronic therapy with Nonsteroidal anti-inflammatory drugs (NSAIDs)
- •Treated with a Vitamin K antagonist in the 30 days prior to screening
研究组 & 干预措施
BAY2433334 matching placebo+Apixaban
Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
干预措施: Apixaban (Drug)
BAY2433334 50mg+Apixaban matching placebo
干预措施: BAY2433334 (Drug)
BAY2433334 50mg+Apixaban matching placebo
干预措施: Apixaban matching placebo (Other)
BAY2433334 20mg+Apixaban matching placebo
干预措施: BAY2433334 (Drug)
BAY2433334 20mg+Apixaban matching placebo
干预措施: Apixaban matching placebo (Other)
BAY2433334 matching placebo+Apixaban
Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.
干预措施: BAY2433334 matching placebo (Other)
结局指标
主要结局
Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
时间窗: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.
次要结局
- Number of Participants With All Bleeding(After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration))
- Number of Participants With ISTH Minor Bleeding(After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration))
- Number of Participants With ISTH Major Bleeding(After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration))
- Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding(After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration))